Novo Nordisk on Wednesday announced an expanded deal with healthtech firm Valo Health to use AI to fuel drug discovery.

FOIA requests to the federal government often are signals. They can be an important early warning of bad publicity, litigation to come, or uncertainties to be hedged and gamed out. When the flow of ...

El Lilly’s (LLY) blockbuster weight-loss drug Zepbound is now eligible for Medicare coverage. The news could significantly ...

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

President-elect Donald Trump threatened Tuesday to place new tariffs on imports from Denmark unless the country gives up control of Greenland, news that dented the stocks of some of Denmark's most ...

Recent market research reveals that glucagon-like peptide-1 (GLP-1) injections are set to dominate the obesity treatment ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other ...

The Dow, S&P 500, and Nasdaq are struggling to find a direction Wednesday as the stock market braces for minutes from the Fed's monetary policy meeting.

Eli Lilly's Tirzepatide Outshines Novo Nordisk's Semaglutide, Yet Brand Recognition Remains Strong for Novo's Products ...

To identify this year’s Drugs to Watch 2025 list, Clarivate drew from expertise from over 160 Clarivate analysts covering ...

The UK's self-regulated system for disclosing payments from drug companies to healthcare professionals and organisations is failing to protect ...